Urologists’ Estimation of Online Support Group Utilization Behavior of Their Patients With Newly Diagnosed Nonmetastatic Prostate Cancer in Germany: Predefined Secondary Analysis of a Randomized Controlled Trial
Philipp Karschuck(Heidelberg University), Johannes Huber(Heidelberg University), Joachim Stein(Klinikum Region Hannover), Philipp Spiegelhalder(Neanderthal Museum), Andreas Ihrig(Heidelberg University), Tanja Krones(University Hospital Zurich), Martin Baunacke(Technische Universität Dresden), Christian Klopf(Vivantes Klinikum), Sven von Ahn(Krankenhaus der Barmherzigen Brüder Trier), Christer Groeben(Philipps University of Marburg), C. Weißflog(Advanced Mask Technology Center (Germany)), Georgi Tosev(Heidelberg University), P. Liske(Institut Dr. Flad), Martin Schostak(Aturo), Christian Thomas(Hôpital des Diaconesses), Rainer Koch(Heidelberg University), Andreas Neisius(Trier University of Applied Sciences), Steffen Weikert(St. Hedwig-Krankenhaus), Michael Siebels, Nicolas Haseke(München Klinik), Thomas Benusch(Schön Klinik Neustadt)
Cited by 2
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Best Practice in Interventional Management of Urolithiasis: An Update from the European Association of Urology Guidelines Panel for Urolithiasis 2022
|European Urology Focus|2022|252
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
|International Journal of Molecular Medicine|2005|151